The status of the Ozempic & Wegovy litigation is that these legal actions have been consolidated into Multidistrict Litigation (MDL) No. 3094 in the Eastern District of Pennsylvania. The aim is to streamline pretrial proceedings.
If you took either of these medications and they had a negative effect on your health, turn to a Charlotte Ozempic & Wegovy lawsuit lawyer. They can help you take legal action against the liable party.
Overview of the Litigation
MDL No. 3094 encompasses over 1,500 personal injury lawsuits filed by individuals who have experienced adverse effects after using Ozempic, Wegovy, and similar medications.
These drugs are known to be effective for managing type 2 diabetes and obesity. However, plaintiffs allege that they also carry risks of serious gastrointestinal issues and vision impairment.
They claim that Novo Nordisk failed to adequately warn patients and healthcare providers about these potential side effects.
For a free legal consultation, call (877) 333-1000
Key Legal Developments
If you are considering taking legal action against Novo Nordisk related to Ozempic or Wegovy, it’s important that you understand the current status of this litigation.
Discovery and Evidence Challenges
A pivotal aspect of the litigation involves the scope of discovery. Plaintiffs have sought access to marketing materials and promotional content to demonstrate that Novo Nordisk‘s marketing strategies may have downplayed the risks associated with their drugs.
However, the court has limited early discovery to focus on the adequacy of the FDA-approved warning labels, excluding broader marketing materials at this stage. Plaintiffs argue that this restriction hampers their ability to present a comprehensive case.
Motion to Dismiss Peripheral Claims
In January 2025, Novo Nordisk filed a motion to dismiss several secondary claims, including fraudulent misrepresentation and design defect. The court’s decision on this motion could significantly impact the scope of the litigation. However, the central failure–to–warn claims remain unaffected and continue to form the core of the plaintiffs’ arguments.
Daubert Hearing Scheduled
A critical evidentiary hearing is scheduled for May 14, 2025, under Federal Rule of Evidence 702. This Daubert hearing will assess the scientific validity of expert testimony linking Ozempic and Wegovy to gastroparesis.
The outcome of this hearing is crucial. Because it will determine whether expert opinions can be presented in court, it could potentially influence the strength of the plaintiffs’ cases.
Individual Lawsuits and Allegations
Beyond the consolidated MDL, numerous individual lawsuits have been filed against Novo Nordisk related to damage caused by Ozempic and Wegovy. They assert that gastrointestinal damage and other problems arising from the use of these medications have resulted in serious health problems.
Novo Nordisk has denied the allegations. Instead, the company claims that these lawsuits are without merit and that its medications have a long history of safe use when taken as directed.
Click to contact our personal injury lawyers today
Regulatory and Medical Perspectives
The U.S. Food and Drug Administration (FDA) has been monitoring reports of adverse events associated with GLP-1 receptor agonists. In response to emerging concerns, the FDA updated the warning labels for these medications in October 2024 to include risks such as pulmonary aspiration, where stomach contents enter the lungs during surgery.
Additionally, a 2024 study published in JAMA Ophthalmology found an association between semaglutide, the active ingredient in Ozempic and Wegovy, and an eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). This prompted further investigations into the drugs’ safety profile.
Complete a Free Case Evaluation form now
Future Outlook
The litigation surrounding Ozempic and Wegovy is expected to continue evolving in the coming months. The scheduled Daubert hearing in May 2025 will be a significant event, as it could influence the admissibility of expert testimony and the overall direction of the cases.
Furthermore, the outcome of the motion to dismiss secondary claims could affect the scope of the litigation as well. As the legal proceedings unfold, both parties are likely to continue presenting evidence and arguments to support their positions.
Get Help from an Experienced Legal Team
The status of the Ozempic and Wegovy litigation is marked by ongoing legal battles, with plaintiffs alleging serious health risks associated with these medications and seeking accountability from Novo Nordisk.
At DeMayo Law Offices, we can help you add your case to the ongoing litigation against this company. We have recovered over $1 billion in damages for our clients since founding our firm in 1992.
Our dedicated, supportive, and compassionate team will use our vast body of legal knowledge and experience to help you build a strong case for full compensation for your losses.
Reach out to us by phone or through our website to schedule a free case review with a law firm that offers exceptional service with exceptional results. We firmly believe in People Over Profits™ and are prepared to put that belief into action for you.
Call or text (877) 333-1000 or complete a Free Case Evaluation form
